Published in Lancet on March 05, 2009
Prior Axitinib as a Determinant of Outcome of Renal Surgery (PADRES) | NCT03438708
Novel Biomarkers of Hypoxia and Metabolism in Clear Cell Renal Cell Carcinoma | NCT05214885
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature (2010) 14.50
Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet (2013) 4.61
Fructose-1,6-bisphosphatase opposes renal carcinoma progression. Nature (2014) 3.80
Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat Genet (2011) 3.66
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature (2011) 3.53
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget (2011) 3.43
von Hippel-Lindau disease: a clinical and scientific review. Eur J Hum Genet (2011) 2.45
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget (2012) 1.96
Integrated profiling of microRNAs and mRNAs: microRNAs located on Xq27.3 associate with clear cell renal cell carcinoma. PLoS One (2010) 1.82
Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. PLoS One (2012) 1.80
Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol Cancer Ther (2010) 1.70
FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis. Cancer Cell (2010) 1.58
Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. Clin Cancer Res (2014) 1.57
Estimation of renal cell carcinoma treatment effects from disease progression modeling. Clin Pharmacol Ther (2012) 1.55
Evaluation of Urine Aquaporin-1 and Perilipin-2 Concentrations as Biomarkers to Screen for Renal Cell Carcinoma: A Prospective Cohort Study. JAMA Oncol (2015) 1.51
Overexpression of wip1 is associated with biologic behavior in human clear cell renal cell carcinoma. PLoS One (2014) 1.48
The VHL-dependent regulation of microRNAs in renal cancer. BMC Med (2010) 1.46
Retracted Up-regulation of pVHL along with down-regulation of HIF-1α by NDRG2 expression attenuates proliferation and invasion in renal cancer cells. PLoS One (2013) 1.40
Association between R.E.N.A.L. nephrometry score and perioperative outcomes following open partial nephrectomy under cold ischemia. Can Urol Assoc J (2014) 1.38
High expression of long non-coding RNA SPRY4-IT1 predicts poor prognosis of clear cell renal cell carcinoma. Int J Clin Exp Pathol (2014) 1.37
Urinary biomarkers for the early diagnosis of kidney cancer. Mayo Clin Proc (2010) 1.24
Advances in the genetics of familial renal cancer. Oncologist (2010) 1.23
Treatment selection in metastatic renal cell carcinoma: expert consensus. Nat Rev Clin Oncol (2012) 1.19
AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. Cancer (2012) 1.17
microRNA-155 silencing inhibits proliferation and migration and induces apoptosis by upregulating BACH1 in renal cancer cells. Mol Med Rep (2012) 1.15
Comparative mRNA and microRNA expression profiling of three genitourinary cancers reveals common hallmarks and cancer-specific molecular events. PLoS One (2011) 1.15
Integrative genomic analyses of sporadic clear cell renal cell carcinoma define disease subtypes and potential new therapeutic targets. Cancer Res (2011) 1.12
Prognostic role of the neutrophil-lymphocyte ratio in renal cell carcinoma: a meta-analysis. BMJ Open (2015) 1.11
SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer. Cancer Cell (2014) 1.11
Critical appraisal of sorafenib in the treatment of Chinese patients with renal cell carcinoma. Onco Targets Ther (2014) 1.10
Targeting the tumor microenvironment: focus on angiogenesis. J Oncol (2011) 1.09
A panel of five serum miRNAs as a potential diagnostic tool for early-stage renal cell carcinoma. Sci Rep (2015) 1.09
Renal cancer biomarkers: the promise of personalized care. BMC Med (2012) 1.08
Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib. Mol Cancer (2011) 1.07
miR-145 functions as tumor suppressor and targets two oncogenes, ANGPT2 and NEDD9, in renal cell carcinoma. J Cancer Res Clin Oncol (2014) 1.07
An emerging understanding of long noncoding RNAs in kidney cancer. J Cancer Res Clin Oncol (2014) 1.07
Characterization of long non-coding RNA transcriptome in clear-cell renal cell carcinoma by next-generation deep sequencing. Mol Oncol (2014) 1.04
Overexpression of FoxM1 is associated with tumor progression in patients with clear cell renal cell carcinoma. J Transl Med (2012) 1.03
'Image and treat': an individualized approach to urological tumors. Curr Opin Oncol (2010) 1.03
Targeted therapies for non-clear renal cell carcinoma. Target Oncol (2010) 1.02
FoxO transcription factors promote AKT Ser473 phosphorylation and renal tumor growth in response to pharmacologic inhibition of the PI3K-AKT pathway. Cancer Res (2014) 1.02
Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients. J Pathol (2011) 1.02
Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models. Mol Cancer Ther (2014) 1.01
Multi-modal treatment for metastatic renal cancer: the role of surgery. World J Urol (2010) 1.01
Epigenetic regulation in RCC: opportunities for therapeutic intervention? Nat Rev Urol (2012) 0.99
GOLPH3 is a novel marker of poor prognosis and a potential therapeutic target in human renal cell carcinoma. Br J Cancer (2014) 0.98
Expression and significance of histone H3K27 demethylases in renal cell carcinoma. BMC Cancer (2012) 0.97
Comparison of radiographic and pathologic sizes of renal tumors. World J Urol (2010) 0.97
Down-regulation of miR-497 is associated with poor prognosis in renal cancer. Int J Clin Exp Pathol (2015) 0.96
Proteostasis modulators prolong missense VHL protein activity and halt tumor progression. Cell Rep (2013) 0.96
Ubiquitin specific peptidase 21 regulates interleukin-8 expression, stem-cell like property of human renal cell carcinoma. Oncotarget (2016) 0.95
HGIMDA: Heterogeneous graph inference for miRNA-disease association prediction. Oncotarget (2016) 0.95
The FoxO-BNIP3 axis exerts a unique regulation of mTORC1 and cell survival under energy stress. Oncogene (2013) 0.93
ABO blood group and risk of renal cell cancer. Cancer Epidemiol (2012) 0.93
DNA methylation profiling reveals novel diagnostic biomarkers in renal cell carcinoma. BMC Med (2014) 0.92
A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models. PLoS One (2013) 0.92
Underexpression of tumour suppressor LKB1 in clear cell renal cell carcinoma is common and confers growth advantage in vitro and in vivo. Br J Cancer (2013) 0.92
Correlation of the RENAL nephrometry score with warm ischemia time after robotic partial nephrectomy. World J Urol (2012) 0.91
Overexpression of SATB1 is associated with biologic behavior in human renal cell carcinoma. PLoS One (2014) 0.91
The specificity of urinary aquaporin 1 and perilipin 2 to screen for renal cell carcinoma. J Urol (2012) 0.91
Role of imaging in successful management of malignant ovarian vein thrombosis in RCC. BMJ Case Rep (2014) 0.91
Imaging angiogenesis of genitourinary tumors. Nat Rev Urol (2010) 0.90
Valproic acid upregulates NKG2D ligand expression and enhances susceptibility of human renal carcinoma cells to NK cell-mediated cytotoxicity. Arch Med Sci (2013) 0.90
Decreased expression of a novel lncRNA CADM1-AS1 is associated with poor prognosis in patients with clear cell renal cell carcinomas. Int J Clin Exp Pathol (2014) 0.90
Circulating biomarkers in advanced renal cell carcinoma: clinical applications. Curr Oncol Rep (2012) 0.89
Updates on novel therapies for metastatic renal cell carcinoma. Ther Adv Med Oncol (2010) 0.89
The epigenetics of renal cell tumors: from biology to biomarkers. Front Genet (2012) 0.89
A serum-circulating long noncoding RNA signature can discriminate between patients with clear cell renal cell carcinoma and healthy controls. Oncogenesis (2016) 0.88
Vascular endothelial growth factor gene polymorphisms and renal cell carcinoma: A systematic review and meta-analysis. Oncol Lett (2013) 0.88
Lysophosphatidic acid activates Arf6 to promote the mesenchymal malignancy of renal cancer. Nat Commun (2016) 0.88
Determination of angptl4 mRNA as a diagnostic marker of primary and metastatic clear cell renal-cell carcinoma. PLoS One (2010) 0.88
Integrated optical coherence tomography and optical coherence microscopy imaging of ex vivo human renal tissues. J Urol (2011) 0.88
Everolimus - a new approach in the treatment of renal cell carcinoma. Cancer Manag Res (2010) 0.87
Renal cell carcinoma metastasis to the ovary: a case report. Cases J (2009) 0.87
Hippo signaling mediates proliferation, invasiveness, and metastatic potential of clear cell renal cell carcinoma. Transl Oncol (2014) 0.87
Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting. PLoS One (2012) 0.86
Impact of miR-21, miR-126 and miR-221 as prognostic factors of clear cell renal cell carcinoma with tumor thrombus of the inferior vena cava. PLoS One (2014) 0.86
Inactivation of the von Hippel-Lindau tumour suppressor gene induces Neuromedin U expression in renal cancer cells. Mol Cancer (2011) 0.85
Low Expression of Mucin-4 Predicts Poor Prognosis in Patients With Clear-Cell Renal Cell Carcinoma. Medicine (Baltimore) (2016) 0.85
Upregulation of centromere protein H is associated with progression of renal cell carcinoma. J Mol Histol (2015) 0.85
PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence. Onco Targets Ther (2014) 0.85
Regulation of the collagen cross-linking enzymes LOXL2 and PLOD2 by tumor-suppressive microRNA-26a/b in renal cell carcinoma. Int J Oncol (2016) 0.85
Cytoreductive nephrectomy and its role in the present-day period of targeted therapy. Ther Adv Urol (2015) 0.85
PIK3R1 negatively regulates the epithelial-mesenchymal transition and stem-like phenotype of renal cancer cells through the AKT/GSK3β/CTNNB1 signaling pathway. Sci Rep (2015) 0.85
Let-7d suppresses growth, metastasis, and tumor macrophage infiltration in renal cell carcinoma by targeting COL3A1 and CCL7. Mol Cancer (2014) 0.85
The blind spots in follow-up after nephrectomy or nephron-sparing surgery for localized renal cell carcinoma. World J Urol (2014) 0.85
Retrospective Analysis of the Efficacy and Safety of Sorafenib in Chinese Patients With Metastatic Renal Cell Carcinoma and Prognostic Factors Related to Overall Survival. Medicine (Baltimore) (2015) 0.85
Distinct von Hippel-Lindau gene and hypoxia-regulated alterations in gene and protein expression patterns of renal cell carcinoma and their effects on metabolism. Oncotarget (2015) 0.84
Deregulation of E2-EPF ubiquitin carrier protein in papillary renal cell carcinoma. Am J Pathol (2011) 0.84
p21-activated kinase 1 determines stem-like phenotype and sunitinib resistance via NF-κB/IL-6 activation in renal cell carcinoma. Cell Death Dis (2015) 0.84
Adoptive cellular immunotherapy in metastatic renal cell carcinoma: a systematic review and meta-analysis. PLoS One (2013) 0.84
Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer. Br J Cancer (2010) 0.84
Suppression of PGC-1α Is Critical for Reprogramming Oxidative Metabolism in Renal Cell Carcinoma. Cell Rep (2015) 0.84
Xp11.2 translocation renal cell carcinomas in young adults. BMC Urol (2015) 0.83
Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis. Int J Clin Oncol (2012) 0.83
Stage-related alterations in renal cell carcinoma--comprehensive quantitative analysis by 2D-DIGE and protein network analysis. PLoS One (2011) 0.83
Prognostic Significance of Hypoxia-Inducible Factor Expression in Renal Cell Carcinoma: A PRISMA-compliant Systematic Review and Meta-Analysis. Medicine (Baltimore) (2015) 0.83
Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib. Biologics (2010) 0.83
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (2008) 19.58
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (2011) 12.13
Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer (2010) 7.25
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol (2008) 5.27
Malignant effusions and immunogenic tumour-derived exosomes. Lancet (2002) 4.91
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 4.24
Emphysematous cystitis: a review of 135 cases. BJU Int (2007) 4.08
The epidemiology of renal cell carcinoma. Eur Urol (2011) 3.85
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol (2013) 3.79
Every minute counts when the renal hilum is clamped during partial nephrectomy. Eur Urol (2010) 3.71
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature (2011) 3.53
Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol (2013) 3.31
Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol (2013) 3.20
Renal mass biopsy--a renaissance? J Urol (2007) 3.12
CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med (2005) 2.93
Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol (2005) 2.85
Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. Cancer (2013) 2.61
Parenchymal volume preservation and ischemia during partial nephrectomy: functional and volumetric analysis. Urology (2013) 2.59
Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J Clin Oncol (2012) 2.56
Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol (2013) 2.53
Metastatic renal cell carcinoma. Curr Treat Options Oncol (2003) 2.50
Comparison of warm ischemia versus no ischemia during partial nephrectomy on a solitary kidney. Eur Urol (2010) 2.38
Surgical resection of renal cell carcinoma after targeted therapy. J Urol (2009) 2.29
Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. Clin Cancer Res (2011) 2.27
Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin Cancer Res (2010) 2.26
Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol (2010) 2.19
Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol (2011) 2.17
Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol (2009) 2.16
Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie. J Clin Oncol (2004) 2.05
Elective partial nephrectomy in patients with clinical T1b renal tumors is associated with improved overall survival. Urology (2010) 2.04
Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol (2008) 2.03
Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series. Cancer (2009) 2.02
Functional recovery after partial nephrectomy: effects of volume loss and ischemic injury. J Urol (2012) 1.90
Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population. Eur Urol (2011) 1.87
Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J Immunol (2004) 1.86
Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol (2009) 1.83
Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J Clin Oncol (2010) 1.80
ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. Eur Urol (2011) 1.80
Inadequacy of biopsy for diagnosis of upper tract urothelial carcinoma: implications for conservative management. Urology (2011) 1.78
Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. Cancer (2010) 1.77
Metabolism of kidney cancer: from the lab to clinical practice. Eur Urol (2012) 1.75
Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst (2012) 1.72
Renal functional outcomes after partial nephrectomy with extended ischemic intervals are better than after radical nephrectomy. J Urol (2010) 1.71
Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. PLoS One (2009) 1.70
Performance of the chronic kidney disease-epidemiology study equations for estimating glomerular filtration rate before and after nephrectomy. J Urol (2010) 1.69
Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med (2010) 1.66
Partial nephrectomy does not compromise survival in patients with pathologic upstaging to pT2/pT3 or high-grade renal tumors compared with radical nephrectomy. Urology (2011) 1.64
Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma. BJU Int (2012) 1.64
A preoperative prognostic nomogram for solid enhancing renal tumors 7 cm or less amenable to partial nephrectomy. J Urol (2007) 1.57
Single institutional cost analysis of 325 robotic, laparoscopic, and open partial nephrectomies. Urology (2013) 1.56
Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer (2005) 1.55
Clinical correlates of renal angiomyolipoma subtypes in 209 patients: classic, fat poor, tuberous sclerosis associated and epithelioid. J Urol (2008) 1.55
Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst (2008) 1.53
Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. Cancer (2010) 1.53
Partial nephrectomy is associated with improved overall survival compared to radical nephrectomy in patients with unanticipated benign renal tumours. Eur Urol (2010) 1.52
Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer (2010) 1.52
Renal function after partial nephrectomy: effect of warm ischemia relative to quantity and quality of preserved kidney. Urology (2012) 1.52
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res (2011) 1.52
Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. Eur Urol (2012) 1.50
Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol (2008) 1.49
Bilateral synchronous sporadic renal tumors: pathologic concordance and clinical implications. Urology (2011) 1.45
Fenoldopam and renal function after partial nephrectomy in a solitary kidney: a randomized, blinded trial. Urology (2013) 1.44
Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J Immunol (2004) 1.43
[Kidney tumors]. Prog Urol (2007) 1.43
Enhanced computed tomography after partial nephrectomy in early postoperative period to detect asymptomatic renal artery pseudoaneurysm. Int J Urol (2014) 1.43
Five to 10-year followup of open partial nephrectomy in a solitary kidney. J Urol (2013) 1.42
How to interpret phase II data for everolimus plus bevacizumab in renal cell carcinoma. J Clin Oncol (2010) 1.41
Surgically induced chronic kidney disease may be associated with a lower risk of progression and mortality than medical chronic kidney disease. J Urol (2012) 1.40
Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. Int J Cancer (2002) 1.37
Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol (2008) 1.33
Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol (2005) 1.30
Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma. J Immunol (2005) 1.30
Effect of parenchymal volume preservation on kidney function after partial nephrectomy. J Urol (2011) 1.25
Sequential use of targeted agents in the treatment of renal cell carcinoma. Crit Rev Oncol Hematol (2010) 1.22
Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol (2010) 1.22
Laparoscopic renal cryosurgery: the Northwestern experience. J Urol (2003) 1.20
Adult cystic nephroma and mixed epithelial and stromal tumor of the kidney: clinical, radiographic, and pathologic characteristics. Urology (2008) 1.20
Histopathologic features and clinical outcomes in 71 cases of bladder diverticula. Arch Pathol Lab Med (2009) 1.19
Robotic and laparoscopic radical cystectomy for bladder cancer: long-term oncologic outcomes. Eur Urol (2013) 1.18
Hypoxia promotes tumor growth in linking angiogenesis to immune escape. Front Immunol (2012) 1.18
AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. Cancer (2012) 1.17
Familial non-VHL clear cell (conventional) renal cell carcinoma: clinical features, segregation analysis, and mutation analysis of FLCN. Clin Cancer Res (2008) 1.17
Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol (2007) 1.17
Transcription factor E3 and transcription factor EB renal cell carcinomas: clinical features, biological behavior and prognostic factors. J Urol (2010) 1.16
Mixed epithelial and stromal tumor of the kidney and cystic nephroma share overlapping features: reappraisal of 15 lesions. Arch Pathol Lab Med (2006) 1.16
Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma. J Med Genet (2011) 1.14
Diameter-axial-polar nephrometry: integration and optimization of R.E.N.A.L. and centrality index scoring systems. J Urol (2012) 1.14
Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma. Hematol Oncol Clin North Am (2011) 1.13
Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies. Cancer (2013) 1.13
To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur J Cancer (2006) 1.12
Gonadal vein tumor thrombus in metastatic renal cell carcinoma. Urology (2009) 1.12
Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. Genome Med (2010) 1.12
A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin Cancer Res (2009) 1.12